Wealth Enhancement Advisory Services LLC Has $84,000 Stock Holdings in Omeros Corporation $OMER

Wealth Enhancement Advisory Services LLC cut its holdings in Omeros Corporation (NASDAQ:OMER) by 62.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 26,156 shares of the biopharmaceutical company’s stock after selling 44,242 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Omeros were worth $84,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in OMER. Acadian Asset Management LLC bought a new position in Omeros in the first quarter valued at about $357,000. Trexquant Investment LP bought a new position in Omeros in the first quarter valued at about $88,000. Hsbc Holdings PLC bought a new position in Omeros in the first quarter valued at about $142,000. Wellington Management Group LLP bought a new position in Omeros in the first quarter valued at about $1,118,000. Finally, Nuveen LLC bought a new position in Omeros in the first quarter valued at about $938,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

OMER has been the topic of several recent research reports. Wall Street Zen upgraded Omeros from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Friday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Omeros in a report on Friday, June 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $36.00 price target on shares of Omeros in a report on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Omeros Price Performance

NASDAQ OMER opened at $4.19 on Monday. The firm has a market cap of $285.17 million, a P/E ratio of -1.99 and a beta of 2.32. The stock’s 50-day moving average is $4.23 and its 200-day moving average is $4.53. Omeros Corporation has a one year low of $2.95 and a one year high of $13.60.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.02. The business had revenue of $28.60 million for the quarter, compared to analyst estimates of $0.31 million. Equities analysts anticipate that Omeros Corporation will post -3.09 EPS for the current year.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.